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Haemagglutinin-neuraminidase from HPIV3 mediates human
NK regulation of T cell proliferation via NKp44 and NKp46
Samantha McQuaid,1† Sinead Loughran,1,2 Patrick Power,1,3 Paula Maguire,1 Dermot Walls,4 Maria Grazia Cusi,5
Claes Orvell6 and Patricia Johnson1,*

Abstract
HPIV3 is a respiratory virus causing airway diseases, including pneumonia, croup, and bronchiolitis, during infancy and
childhood. Currently there is no effective vaccine or anti-viral therapy for this virus. Studies have suggested that poor T cell
proliferation following HPIV3 infection is responsible for impaired immunological memory associated with this virus. We
have previously demonstrated that NK cells mediate regulation of T cell proliferation during HPIV3 infection. Here we add to
these studies by demonstrating that the regulation of T cell proliferation during HPIV3 infection is mediated via NK receptors
NKp44 and NKp46 and involves the surface glycoprotein haemagglutinin-neuraminidase but not the fusion protein of the
virus. These studies extend our knowledge of the regulatory repertoire of NK cells and provide mechanistic insights which
may explain reoccurring failures of vaccines against this virus.

demonstrate that HPIV3 surface glycoprotein haemagglutinin-neuraminidase (HN) but not the fusion (F) protein
induces NK cell-mediated inhibition of T cell proliferation
during HPIV3 infection. In addition, we show that viral
interaction with NKp46 and NKp44 but not NKp30 drives
T cell cycle arrest in these cultures. NKp46, NKp44 and
NKp30 are known collectively as natural cytotoxicity receptors (NCRs) [8]. NKp46 (also known as NCR1/CD335),
NKp44 (also known as NCR2/CD336) and NKp30 (also
known as NCR3/CD337) are all expressed by NK cells and
play an essential role in NK-mediated recognition and killing of target cells [9]. NKp46 is the only NCR to also have a
mouse orthologue (mNKp4619) and it directly recognizes
the haemagglutinin protein of numerous viruses including
influenza, as well as self and tumour ligands [10]. NKp44 is
not expressed in mice and to date, has only been found to
have orthologues in humans and non-human primates [11].
It is expressed exclusively on activated NK cells and depending on the ligand it binds to, it can have an activating or
inhibitory effect [12, 13]. Of additional interest, we found

Human parainfluenza virus type 3 (HPIV3) is a major respiratory pathogen which is responsible for pneumonia, croup
and bronchiolitis in infants and children [1–3]. Reinfection
with this virus throughout life is common, with no development of lifelong immunity. Even in the presence of circulating neutralizing antibodies, individuals have been shown to
be susceptible to reinfection [3, 4]. It has been suggested
that reinfection with HPIV3 occurs due to the failure of
T cell proliferation to the virus [5, 6]. Previously published
data from our group demonstrated that human NK cells
induce T cell cycle arrest in a contact-dependent manner
during infection with this virus and this regulation does not
occur in the absence of the NK population. NK regulation
was also associated with reduced levels of interleukin-2
(IL-2) production during HPIV3 infection, and the addition
of exogenous IL-2 could override the NK-induced inhibition
of T cell proliferation [7]. While these studies suggested a
mechanism to explain the failed memory associated with
HPIV3 infection, the viral components involved and the
mode of NK cell regulation remained unclear. Here we
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infection with the same strain of influenza) for 2 h at
37  C. Cells were washed to remove extracellular virions
and incubated for a further 20–24 h to allow maturation to
antigen-presenting cells (APCs). Reverse transcription PCR
for nucleoprotein was performed to confirm that infection
had occurred in HPIV3 and influenza virus-infected cells.
PCR parameters consisted of 5 min at 95  C, followed by
35 cycles of denaturation at 95  C for 45 s, annealing (temperature varied with primers) for 45 s, and extension at
72  C for 10 min. Amplification was performed in 25 µl
reactions containing 400 pmol of each primer, 2 mM
deoxyribonucleotide triphosphates, 10X PCR buffer
(Promega), 2.5 mM Mg2+, 1.25 U of Taq DNA Polymerase
(Promega) and 1 µl of cDNA. The primer sequences for
the genes examined were as follows: HPIV3 forward,
TTGGAAGTGACCTGGATTAT; reverse, GGATACAGA

that although the overall CD3+ T cell numbers are reduced,
the levels of regulatory T (Treg) cells increased in line with
NK cells during HPIV3 infection.
To conduct these experiments, CD14+ monocytes were
purified from human PBMCs (obtained from buffy coats
of healthy donors from the Irish blood transfusion service)
to >90 % using magnetic-activated cells sorting (MACS)
via magnetic anti-CD14 microbeads. These cells (1106
ml 1) were cultured in RPMI (with 10 % FCS, 1 % L-glutamine and 1 % penicillin/streptomycin) and were untreated,
infected with HPIV3 (strain C-243, ATCC; Accession
number: D10025.1; 50 % TCID50 ml 1 of 106) or influenza
virus (A/Puerto-Rico/8/34(H1N1), a generous gift from
NIBSC, UK; TCID50 ml 1 of 107) (a respiratory virus associated with acute as opposesd to persistent or recurrent

Fig. 1. Effect of neutralizing antibodies to HPIV3 surface glycoproteins on NK cell-mediated T cell inhibition. Isolated CD14+ cells were
infected with HPIV3 or influenza, washed after 2 h, and co-cultured with allogeneic mixed lymphocytes after 24 h. Prior to co-culture,
HPIV3-infected CD14+ cells were cultured with Anti-Canine Distemper Virus (A-CDV), Anti-HN (A-HN) or Anti-F (A-F) antibodies in some
cases. Media samples, and PMA and Anti-CD3 (A-CD3) stimulated mixed lymphocytes (MLs) were also included. After 5 days, these
were assessed for overall ML proliferation by MTS (a), or the percentage of cells expressing NK cell markers (CD56+CD3) were determined by flow cytometry (b). Additionally, IL-2 levels in supernatants were determined by ELISA (c). The percentage of CD3+ cells in
the G0/G1 phase of the cell cycle was determined by PI staining and flow cytometry analysis (d). These experiments were repeated,
isolated CD56+ and CD3+ cells, with CFSE incorporated into the latter (e). These were again co-cultured with allogeneic-infected and
antibody-treated CD14+ cells. All experiments represent normalized results from three donors in triplicate. Significance was determined using the Newman–Keuls test to compare all parameters, with comparisons indicated on graphs. ***P0.001.
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TAAAAGGAGC; influenza virus forward, CTTACGAACAGATGGAGACT; reverse, TGTTTTCCGCCCATTC
TCAC; human b-actin forward, TACAATGAGCTGCGTG
TG; reverse, TGTTGGCGTACAGGTCTT. DNA electrophoresis was performed on a 1 % agarose gel containing
2 µl of ethidium bromide at 100 V for 45 min. Infected or
control APCs were then co-cultured with allogeneic
(CD14-depleted) mixed lymphocytes (2105 ml 1) isolated using MACS via magnetic anti-CD14 microbeads
(Miltenyi Biotec) as previously shown [14]. These cocultures were incubated at 37  C for a further 5 days. Additional mixed lymphocytes were activated with phorbol
myristate acetate (PMA) and anti-CD3 as a positive control. Proliferation was evaluated using the CellTitre 96
Aqueous One Solution Cell Proliferation Assay [MTS
(Promega)] by adding 20 µl MTS solution to 100 µl cell
suspension (6105 cells ml 1) for the last 4 h of incubation.
Carboxyfluorescein succinimidyl ester (CFSE) incorporation was also used to track proliferation of CD3+ T cells
according to manufacturer’s guidelines (Invitrogen). Flow

cytometric analysis of the cell cycle was performed on
alcohol-fixed cells with propidium iodide staining. To
establish the involvement of HPIV3 surface glycoproteins
F and HN, neutralizing antibodies [Anti-HN, Anti-F or
Anti-Canine Distemper Virus (CDV) (control) antibodies;
a generous gift from Professor Claes Orvell, Karolinska
Institute] were co-incubated with HPIV3 infected CD14+
cells at a 1 : 100 vol ratio for 30 min prior to co-culture. To
identify the NK receptors involved, 1 µg Anti-NKp44 or
Anti-NKp46 or Anti-NKp30 were cultured with mixed
lymphocytes prior to co-culture as described for previous
studies [15, 16]. Human IL-2 ELISA kits (R&D) were used
to quantify the cytokine levels in supernatants. Fluorescence conjugated antibodies to CD56, CD3, NKp30,
NKp44 and NKp46 were used to stain cells for detection
by flow cytometry (Becton Dickinson FACs Calibur). To
further prove the involvement of HN and not F, these glycoproteins were purified as previously described [17] and
substituted for HPIV3 viral infection in these cultures.

Fig. 2. The involvement of NCRs in NK cell activation by HPIV3. Isolated CD14+ cells were infected with HPIV3 or influenza, washed
after 2 h, and then co-cultured with allogeneic-mixed lymphocytes after 24 h. Prior to co-culture, HPIV3-infected CD14+ cells were cultured with Anti-Canine Distemper Virus (A-CDV), Anti-HN (A-HN) or Anti-F (A-F) in some cases. Media samples, and PMA and Anti-CD3
stimulated MLs were also included. After 5 days, the percentage of CD56+cells expressing NKp30 (a), NKp44 (b), or NKp46 (c) were
determined by flow cytometry. Similarly, HPIV3-infected CD14+ cells were co-cultured with Anti-NCR (A-NCR) (neutralizing antibody)treated mixed lymphocytes. The effect of these antibodies on mixed lymphocyte proliferation was determined by MTS assay (d). Similarly, CD56+ and CD3+ cells were isolated, with CFSE incorporated into the latter, and treated with Anti-NCR antibodies. These were
again co-cultured with infected CD14+ cells and CD3+ cell proliferation determined by flow cytometry (e). After 24 h incubation, mRNA
expression of HPIV3 N, influenza NP and b-actin from infected cells was determined by RT-PCR (f). All experiments represent three
donors in triplicate. Significance was determined using the Newman–Keuls test to compare all parameters, with comparisons indicated on graphs. ***P0.001, **P0.01, *P0.05.

765

McQuaid et al., Journal of General Virology 2018;99:763–767

change to NKp30 expression during HPIV3 infection
(Fig. 2a) however, we observe an up-regulation of both
NKp44 and NKp46 (Fig. 2b, c) during HPIV3 infection
which is abrogated when HPIV3 HN but not F was
blocked (Fig. 2b, c). Additionally, when either NKp44 or
NKp46 were blocked prior to co-culture with HPIV3infected CD14 cells, mixed lymphocyte proliferation was
restored to levels similar to influenza responses during
infection (Fig. 2d). This restoration was further enhanced
when both receptors were blocked simultaneously, suggesting that these receptors act synergistically. We also
detected significant enhancement of CD3+ T cell proliferation in Anti-HN treated, HPIV3-infected co-cultures when
CD3+ proliferation was measured using CFSE incorporation (Fig. 1e). We obtained confirmation that infection
had occurred in both HPIV3 and influenza virus-infected
cells by detecting for the presence of viral nucleoproteins
(Fig. 2f). Finally, to provide proof of the involvement of
HN we demonstrate that purified HN but not F can mimic
viral infection by inducing NK regulation of T cell proliferation which could be restored by blocking NK receptors
NKp44 and NKp46 (Fig. 3a–f).

We had previously found that HPIV3-infected monocytes
induced NK cell-mediated inhibition of T cell proliferation
in an allogeneic mixed lymphocyte reaction [7]. We now
show that blocking HPIV3 HN but not F on virally
infected monocytes restored all the associated indicators of
NK regulation; firstly mixed lymphocyte and purified CD3
+ T cell (+NK cells) proliferation and IL-2 concentrations
were restored to levels comparable with those induced by
influenza-infected monocytes (Fig. 1a, c). In addition,
Anti-HN antibody treatment resulted in significantly less
lymphocytes retained in the G0/G1 phase of cell cycle during HPIV3 infection (Fig. 1d). Concomitantly, the percentage NK cell CD56+CD3 in Anti-HN-treated cultures
dropped to similar levels detected following polyclonal
activation or influenza infection (Fig. 1c). Neither AntiHPIV3 F or a control antibody to CDV has a significant
impact on NK-induced inhibition of T cell proliferation in
HPIV3-infected co-cultures (Fig. 1a–c). Although treatment with Anti-F did prevent cell cycle arrest, this unlike
HPIV3 HN, did not translate into restoration of actual T
cell proliferation (Fig. 1e). Coincidentally, published data
have shown that the HN from HPIV binds human NKp46
and NKp44 but not human NKp30 [2, 18], although no
functional explanation has been proposed. We therefore
examined the expression of the NCRs; NKp44, NKp46 and
NKp30 during HPIV3 infection. We demonstrate no

This study demonstrates that HN from HPIV3 induces NK
regulation of conventional T cell proliferation in humans. We
also show that HN requires access to NK receptors NKp44
and NKp46 to drive this regulatory response providing a

Fig. 3. Effect of isolated HPIV3 surface glycoproteins on NK cell-mediated T cell inhibition. Mixed lymphocytes were cultured with
HPIV3 HN or F, or Influenza HA, in addition to media and PMA and A-CD3 controls. Allogeneic HPIV3 or Influenza infected CD14+ cells
were also co-cultured with mixed lymphocytes for comparison. After 5 days, these cultures were assessed for overall ML proliferation
by MTS assay (a). The percentage of cells expressing NK cell markers (CD56+CD3-) was investigated by flow cytometry (b). Additionally, IL-2 levels in supernatants were determined by ELISA (c). The percentage of CD3+ cells in the G0/G1 phase was determined by PI
staining (d). The percentage of CD56+ cells expressing NKp44 (e) or NKp46 (f) was analysed by flow cytometry. All experiments represent three donors in triplicate. Significance was determined using the Newman–Keuls test to compare all parameters, with comparisons indicated on graphs. ***P0.001, **P0.01, *P0.05.

766

McQuaid et al., Journal of General Virology 2018;99:763–767

4. Bloom HH, Johnson KM, Jacobsen R, Chanock RM. Recovery of
parainfluenza viruses from adults with upper respiratory illness.
Am J Epidemiol 1961;74:50–59.

functional rationale for previous studies which demonstrate
HPIV3 HN binding to these NK receptors [18, 19]. A recent
study has shown expansion of human CD4+ T cells in ex vivo
human PBMC with overlapping pools of 15-mer peptides
encompassing HPIV3 proteins including HN. It may be that
the peptides chosen for HN may not have interacted with
NKp44/Nkp46 in this study. Furthermore, the authors used
additional cytokines to culture the T cells which included
additional IL-2 for intracellular staining studies. Interestingly
however, in the baseline study on the healthy donors, only the
immune response to HPIV3-F protein reached significance
suggesting that the healthy donors had been exposed to
HPIV3 but had only mounted responses to F and not HN
[20]. We suggest that HPIV3-HN induced NK regulation of
human T cell proliferation is a plausible mechanism for failed
immunological memory in humans. Indeed, this may also
explain the successive failures of vaccines that have involved
the use of this component. We would further suggest that the
success of future vaccines against this important pathogen will
require the generation of modified HN versions that retain
immunogenicity but do not bind/interact with human NKp44
and NKp46.
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